Amneal Pharmaceuticals Inc. (NYSE:AMRX) saw an upside of 3.91% to close Monday at $5.84 after adding $0.22 on the day. The 5-day average trading volume is 706,340 shares of the company’s common stock. It has gained $5.96 in the past week. An average of 954,310 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,116,922.
AMRX’s 1-month performance is 14.06% or $0.72 on its low of $4.69 reached on 09/16/21. The company’s shares have touched a 52-week low of $3.90 and high of $7.45, with the stock’s rally to the 52-week high happening on 03/22/21. YTD, AMRX has achieved 27.79% or $1.27. However, the current price is down -21.56%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Mar 15, 211 days have gone by since the last insider trading activity for Amneal Pharmaceuticals Inc. (AMRX). Todisco Joseph (Executive Vice President) most recently sold 36,330 shares at $6.82 per share on Mar 15. This transaction cost the insider $247,865. Executive Vice President, Shah Nikita, sold 36,330 shares at a price of $6.87 on Mar 15.
The company’s PE ratio for the last five years has touched a high of 97.33 and a low of 7.371. AMRX stock has a beta of 1.18. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 0.86 while the price-to-book (PB) in the most recent quarter is 2.52, with the price to cash flow ratio at 6.88.
Amneal Pharmaceuticals Inc.’s quick ratio for the period ended June 29 was 1.50, with the current ratio over the same period at 2.30 meaning that AMRX stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 8.15, while the total debt to equity was 8.24. In terms of profitability, the gross margin trailing 12 months is 35.80%. The trailing 12-month EBITDA margin is 19.66% while for the period ending June 29; Amneal Pharmaceuticals Inc.’s operating margin was 6.60%. The firm’s gross profit as reported stood at $628.39 million against revenue of $1.99 billion.
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected AMRX to announce $0.18 per share in earnings in its latest quarter, but it posted $0.25, representing a 38.90% surprise. EBITDA for the quarter stood at more than $125.9 million. AMRX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 3.63 billion, with total debt at $2.95 billion. Shareholders hold equity totaling $301.39 million
Let’s look briefly at Amneal Pharmaceuticals Inc. (AMRX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 11 October was 72.82% to suggest the stock is trending Overbought, with historical volatility in this time period at 39.94%.
The stock’s 5-day moving average is $5.58, reflecting a +8.35% or $0.45 change from its current price. AMRX is currently trading +14.29% above its 20-day SMA, +1.39% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +18.46% and +31.83% respectively.
Stochastic %K and %D was 88.49% and 82.84% and the average true range (ATR) pointed at 0.25. The RSI (14) points at 66.79%, while the 14-day stochastic is at 87.10% with the period’s ATR at 0.24. The stock’s 9-day MACD Oscillator is pointing at 0.17 and 0.26 on the 14-day charts.
Analysts offering their rating for AMRX stock have a consensus rating for the stock as Overweight. Currently, 1 brokerage advisors rate AMRX as a “sell,”, while 2 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 1 rates the stock as overweight while 3 have offered a “buy” rating.
What is AMRX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $6.00 and a high of $9.00, with their median price target at $7.00. Looking at these predictions, the average price target given by analysts is for Amneal Pharmaceuticals Inc. (AMRX) stock is $7.40.